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O&dim. ‘f&s study war designed to define the extent ur 
irddbition of tbmmbio activity achieved with eeo&_mclive tiwd 
dose iatrmrmur se&urn heytin canpared with 6xed dose 
s~bcutmteous cakiom hqarin lo patirotr wiving intrewnoos 
strtptokioese for ecote q ywsrd!al infarction. 
&e&.x”& The rote of hq.erin tba’qy during comna~ 
throabotysis with streptokiosse is cnotmversi~t, in part becaose 
lhc &teacy ofdilrxenl mojunclivc hoperin regimens in hibiting 
afiy increases of lbmmbln activity is net known. 
Me&e&. ‘NWy-eigitt paliants treated with 1.5 million U of 
stre0lddnw end 165 me of aseirin for acute mveenrdisl iohrr- 
those given intravenous beparin at I,2 aod 3 b, respectkety (p = 
0.6). Concentratbos of fibrioopeptide A (mean + SEMI at 1 b 
He4 higher in patients withaul (a = 5) than in those with (n = 
23) G&MM isefwm criteria fw wanafiition (76.4 + 25.7 w. 
25.2 t 5.2 nmollliter, p = 082), and at I, 2 ad 3 b 110~ 
s@dticantty towec titb fwd dose intrweoous hepario (IS.4 + 4.8 
vs. 46.7 2 10.2 nm&llter at 1 h, p = O&04) than without beparin. 
Aftw tixed dose subcutane+,ts bcpari. a, 4 b, tibrinopeptide A 
levels were rbuilar in both ~mops despite lowr 8rlivatd partial 
tbmmbuplastin times in patients rb ret&d Ft.& dose subca- 
taneous heoarin. However. fibrinonestidc A was net mosistrntlv 
rupprrssed in ttber gmup (K&3 hose subcutaneous hepa& 
8.7 2 1.8 nmalillter vs. 6xed dare iotnwneur hrpsrin 11.8 2 5.2 
nmolititert at 48 b (p = 0.4). No ~i~ifi~~~t-~h~~~ in the 
concentration uf thmmbin-antithmmbio 111 complexes WN 
found b&wn tbe t-m gmups. 
cod dslmplo~ therapy [n = 141) or tixfd dose iratrnwnous 
bcpmin (5,~U bdus fallowd by WC-U/h infusion In = 141). 
Antlca@rtlaa ms arwxd with serial mtwwemmts of acti- 
vated ptl!al thmmbofdastlo tfme, and thmmbin aaivity by 
measm’iq asriwppttde A sod tbmoblwntitbmmbin IU mm- 
pla kvelr Ftasmo conccntmtioas of crmtlnc tdnrse (CK) MM 
Isoforms rare wswd for 3 b to dctermlne r~aoaltzstion 
(increw in actlvlty zO.lS%/mio). 
ksrls. Rewafkatiea mnwred in 27%. 64% and 7% of 
@ertt.i &en subcutanmtts bepwin versw 43%, 76% and 86% oi 
In patients treated with tibrinolytic agents for acute myocardial 
infection the benefits of wnjuncdve heporin therapy are still 
controversial (1). This uncertainty is particulrrly applicable to 
streptakinax because the inhibitory effects of fibrinogen deg- 
radation products on fibrin polymerization and platelet qggre- 
gatian may attenuate the risks of recurrent thrombosis (Z-4), 
potentially making eo aggressive regimen of anticoagulation 
less important. The prefercndal route of beparin adminbtra- 
lion is also debated, because the subcutaoeous tixed ose 
Cunclurivnr. Fixed dose iotweacms bepari~ sttenuates in- 
creases in fibbrinopptide A early after st~piotianse. Subsequcot 
tixed dosp intrawmus and rubcuta~~lus bepmin have similar 
effects hut am mlativcly inetleetive in suppressing thmmbin 
activity, suggesting P mle ior mom potent antithmmbin agents 
during camoarj thmmbalysis with stmptobinnse. 
N AIR Cdl cnniial1994;24:1445-52) 
scheme used in clinical trials (5-7) confers variable and often 
suboptimal evels of anticoagulation (8-10). 
Several studies (I l-15) support the concepts that tbrombo- 
lytic therapy cm induce procoagulant activity and that persis- 
tence of incrcased thmmbin activity correlates with the Failure 
of lytic therapy and recurrent hrombosis. lncreoses in throm- 
bin activity are suppreswd by conjunctive intravenous beparin 
in patients treated with recombinant iwe-hipe plnsminopn 
actiwtor (rt-PA), and conjunctive intwcnous heparin appears 
to improve the patency of infarct-relntcd arteries (16.17). 
Howcvcr. the use of heparin during coronary thrombolysis with 
rfreptokinase remains controversial, in part because the et% 
cacy of different conjunctive heparin regimes in inhibiting early 
increases of thrombin activity is not known. Therefore. we 
desigoed this study to compare the xtcot of thromhin activity 
inhibition achieved with conjunctive intrwenous sodium hcp- 
arin with that achieved wilh subculaneous calcium heparin in 
patients treatedwith streptokinase for acute myowdial infarc- 
tion. InhIbition of procoagulant activity was assessed with 
serial measurements offibrinapeptide A, a marker of thrombin isoforms were collected into 7-ml Vacutainer tubs (Becton- 
activity, and thrambin-antithrombin III complex, which re- Dickinson) containing EDNA. Tubes were immediately placed 
flects the quantity of free fhrombin inhibited by antithrombin on ice and centrifuged at l.%lOg for 10 min at 4°C as soon as 
III. Anticoagulation wa monitored by determining activated wss~ble. The Plasma samples were harvested and stored 
partial thromboplastin time. irozn at -70% until they were shipped on dry ice to 
Washington University School of Medicine, where the assavs 
were p&formed (withbr 8 weeks from blood collection). ‘l%e 
samples remained frozen during transfer. 
Samples were obtained at the following time points: base- 
Palent seleciirm. We studied 30 patients who were admit. line, at the end of streptolrinare infusion (1 h). and 2 3.8, 12, 
ted to the coronary care unit bcbveen October 1992 and May 24 and 48 h after mfosion. Measurements of CK-MM isoforms 
1993 and met the following inclusion criteria: 1) typical ante- were performed et beeline and 1.2 and 3 h after streptokinase 
rior chest main of <6 h doration; 2) ST Seement elevation infusion. 
>2 mm in iwo contiguous precmdial cads &I 21 mm in two Blwd was also taken to measure activated partial throm- 
peripheral leads: and 3) no contraindications to thrombulytic bwlartin time and cardiac enzvmes (total and CK-MB olarma . 
therapy. Before entering the study, each patient gave informed a&ity). 
consent. Assay pmtwl. Fibrinopeptide A plasma levels were mea- 
Thmmbolylic and adjuocllve treatmtnt. At the time of sured bv radioimmunoassav. Plasma w s absorbed uitb ten- 
admission, all patients received aspirin 165 mg orally. Sub%* tonitc b&e assay, as pre&usly described (18,19). The con- 
auentlv. thev were randomlv &&ted to receive one of the 
hollowing he&in regimens:‘l) 5,&X-U intravenous bolus of 
centration of fibrinotzeotide A was determined with a 
polyclonal antisera-b&d commercial radioimmunoassay 
sodium heparin (Hoffmann-La Roche AG, Grenzach, Ger- (Byck Sangtek). 
many) immediately followed by a 1.ooOJJ/h infusion through a
constant infusion &~p (n =-IS), or 2) 12,503 U of calcium 
The thrombin-antithmmbin twc-rite enzyme-linked kmu- 
nosorbent assay (ELISA) is specific fir the thrombin- 
hewin fNattermann & Cie. GmbH. Kohln. Germw) liven 
suL&uta&usly every I2 h starting 4 h after the.& of 
antithrombin complex based on a monalanaI antii di- 
rected against a neoantipn on the thrombin-amithrombin 
thrombolyric therapy (n = 15). Immediately after randomiza- wmdu that is not present on free thmmbin. antithrornbin III 
lion. patients were given intravenous treptokiiase (1.5 million or dthcr antithroibin 111 complexes (provided by Baxter 
U over 60 min). Heparin therapy war continued for ~48 h; no Diagnostic%, Inc.). 
attempts were made to modify the heparin dosage in either 
treatr&t group on the basis if rest& of assay if activated 
Creatine kinav MM isofomts were separaled with we of 
the REP (Helens Laboratories) high-voltage eleetrophoresis 
uartinl thromboolastin time. A iixed dose of intravenous 
ieparin was usedbecause this regimen has been shown (16) to 
unit and pwcast wwose eels that have been cwimized by 
Helena fir anai+ of &MB isolom but air0 separ& 
suppress thrombin activity in patients given n-PA. isoforms of C&MM. With this amiautomatcd system, Ipl of 
One patient randomized to receive intravenous heparin did plasma WBF, applied to the gel and ckctro@orcsed for 15 min 
not subsequenrly have a diagnostic rise in cardinc enzyme at 1,4w V. The gel was then owl&i with reagent for coupling 
levels, and one patient randomized to receive subcutaneous 
heparin was found to have a lymphoma (a condition associated 
CK activity with redunion of nimtitinamide-r&nine diiuck- 
otide (NAD), incubated at 49’C for 4.5 min. dried and seanned 
with increases in tibrinowvtide A olasma levels): these or+ 
tients were therefore e&&d from &her analysk, The &al 
in the resident densitometer at 366 nm for Roomcent reduced 
NAD (NADH) product. The proportion of CK-MM romp& 
study group consisted of 28 patients (14 in the subcutaneous ing !he tissue-specific isofomr MM3 was calculated from the 
and 14 in the intravenous heparin group) with documented fluorescence profile of each sample. Result8 were verified by 
acute myocardid infarction. analysis of selected rampIes by both electrophoresis and a 
Ssmpllng protwol. Blood samples were taken by specially qulrntitative chrornatofocusing method validated previously in 
trained nurses with the use of an 18.gauge indwelling catheter our laboratory (20). 
from R forearm vein contralateral to the site of streptokinase Assersma: of wetfusion. TLe owrrence of rewrfusion 
and heparin infusion during the 1st 8 hs. and by separate was detected by an&is of rates oi change of MM3& caku- 
venipunc!ures thereafter. Care was taken to avoid excessive lated es the difference between ulues before and up to 3 h 
blood stasis; samples obtained with difficulty were noted and after lhe onset of treatment divided by the interval between 
discarded. Samples for fibrinopeptide A and thrombin- acwisition of the two snmoles. A rate of chanee of MM3% 
antithrambin II1 complex determinations were collected into >d.lg%lmin was considered indicative of reperkon, as WI- 
3.ml Vacutainer tubes with an anticoagulant solution mntain- i&ted in previous studies (20). 
ing sthylenediaminetetraacetic acid (EDTA), aprotinin and The occurrence of reperfusion was also detected by contin- -. 
o-Phe-L-Pro-L-Arg-chloro-methylketone (PPACK) (fibrin- uous two-lead electrocardiographic (KG) ST segment moni- 
opeptidc A anticoagulant solution, Byck Sangtek, Dietzen- toring (Spacelabs Inc.) during the interval in which blood was 
bath, Germany). Samples for creatine kinase (CK) MM sampled for CK-MM isoforms. Data were not available for 
technical rexsons in three patients so that reperfusion wac 
assessed only by the change in plasma concentrations of 
CK-MM isoform in these subjects. Leads showinx maximal ST 
segment displacement were chosen for anaiysis~Reperfusion 
was defined by abrupt decreases in ST segment elevation (i.e.. 
X0% relative to the most marked e&ion documented ilt 
any time in the stody), as assessed by the analysis of ST 
segment rend graphic printouts. 
All patients undemnt comnsry angiography at a mean of 
5 days from admission. The infarct-related artq ws identi- 
fied on the basis of the sire of ST changes and the presence of 
wall motion abnormalities at left ventriculography. Patency of 
the infarct-related artey ::a assessed according to the Throm- 
bolysis in Myocardiil Infarction (TIMI) criteria (21). The 
infarct-related artery ws considered to be patent if TIMI Hou 
grade was 2 or 3. 
Statistical analysis. We eonsidercd that a sample size of 
-14 patients/treatment group would have had Q 0.9ll power 
with alpha = 0.05, given a 2.5.fold diiicrence m tibrinopeptlde 
A levels between the two patisnt groups (i.e., a ditfercnce less 
than that observed by Ra@d e! al. 1161 in patients giwn rt-PA 
with andwithout concomitant infmvcnous heparia). Values for 
librinopeptide A. thmmbin-antithrombin 111 complex and 
activated partial thromboplastin times did not show a nomlal 
di&ibution; therefore. a logarhhmic transformation WB< per- 
formed before analyzing the data. Because activated partial 
thrombaplastin times still retained a skewed distribution after 
transformation, these data were compared by Mann-Whirney 
U test and expressed as median vaIucs; 25th and 75th percen- 
riks are also reported. Differences in librinopeptide A and 
thmmbin+ntithmmbin III complex levels among groups at 
several time points ‘were evaluated by analysis of variance for 
repeated measures (ANOVA). Signilicancr was computed by 
Sche@ F Tess a p value < 5% was considered significant. 
Comparison amood calegoric variables was performed by the 
chiquare test. Body weight. fibrinopeptide A levels and 
activated partial thromboplastin time were correlated nt each 
time point by Spearman rank correlation. Results are ex- 
pressed BS mean value 2 SEM, unless otherwise stated. The 
STAT ill (Abacus Concepts Inc.) and SPSS 50.2 (SPSS Inc.), 
software were used. 
Results 
Cllaical da& The baseline clinical variables of the two 
study groups are compared in Table I. No significant dihr- 
aces were found between patients treated with subcutaneous 
verws intravenous heparin. 
liel~llao behvcm activated prtial thmmboplaatin time 
and motkolheparia administration. Figure 1 shows activated 
partial thromboplastin time levels in patients treated with 
subcutaneous and intravenous heparin. The median activated 
partial thromboplastin time levels in patients randomized to 
receive subcutaneous heparin (started 4 h after thrombolysis) 
increased 25 times from the baseline value at the end of 
streptokinase infusion. Median activated partial thmmboplas- 
tm tmv prolongation was 2.0 times the baseline value 4 h after 
subcutaneous heparin administration (i.e., at 8 h): however, it 
was only 1.5 times the baseline value at the subsequent time 
pants. In contrast. patients randomized to intravenous hepain 
therapy eubibited activated partial thmmboplnstin times pro- 
longed >.I.4 times (i.e., >I20 s) up to 8 h after lytic treatment, 
when :I progressi\,e decrease was observed. At 48 h, median 
actwated partial thromhoplnstin time was still 2.2 times the 
baseline whtc. Throughout the study period. patients treated 
with inuawnous heparin had si&icantly higher activated 
padal thromboplastin time levels than did those who received 
subcutaneous heparin. 
The relation between the route of heoarin administration 
and the degree of anticoagulation achie&d in the two treat- 
ment wows is illustrated in Figure 2. ht 48 h onlv I65 of 
patienir &ted with subcut&ous heparin had ‘activated 
partial thromboplastin time levels prolonged 22.0 times the 
control Icvcl compared with 68% of those who received 
intravenous heparin (p = 0.04). 
No relation was found behveen activated partial thmmbo- 
Figure 1. EUccts of subcutnneous (sc, open rqusres) versus imrw- 
nw (IV. dad sguares) hep&n on acrivnred partial thromhoplaain 
time (OPTS) during thromboLysir with streptokinasc (SK) Median 
values (squarer) and 25th and 75th percsntiles (bars) me reported. 
Intravenow hcparin was awxiated with signi8cantly higher ncthated 
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pksti” time and body weight in patients treated with intmve- 
DOUS or subcutaneous heparin. 
ilcfatio”behnrntbmmbkl;KiMtyuld~ofLtpvla 
admtnktraUo”. Figure 3 compares changes in the mnantra- 
tkm of fihrinopeptide A after heparin treamtcnt in the two 
patient groups. At baseline, tihrbqeptide A kvck were 
slightiy higher in patients randanired to subcuta”eaus heen 
therapy than in thaw given intravenous hepari”, primarily 
because of two subjects who showed the hi&eat baseline 
tibrinopcptide A levels (42 and 45 nmoliliter, rerpeclively). 
Mer streptokinax (and before heparin) therapy, the subctt- 
taneous heparin group had a signifrant inereiw in fibrbwpep 
tide A levels (from 16.6 + 4.3 to 46.7 2 10.2 “mollliter, p = 
O.Wl); tibrinopeptide A progre.ssively decreased thereafter to 
8.7 + 1.8 nmoVliter at 48 h. At this time point, 3 (27%) of II 
patients had tihrinopeptido A levels 110 nmol/liter. A” in- 
crew in tibrinopeptide A levels was also seen at the end of 
streptokinase infusion in patients treated with intravermus 
heparin (from 7.4 z 1.2 to 18.4 + 4.8 nmobliler, p < 0.01). 
However, this increase was lw pronounced than in the 
absence of early heparin treatment, so that intravenous hepa- 
rin was associated with significantly lower tibtinopcptide A 
levek than was rubeu~lmaus hqwin from 1 to 3 h after lytk 
treatme”t.SMhtgat 8h,howier,wsignifkwd diirences in 
thrmnbin activity were dxwed betwee” tbz twu groups. At 
48 h, tibrinopeptide A Iewk were 11.8 2 5.2 “n~oblitu (p = 
0.4 ys. subcu- hepuio @‘cup). At thk t&e poi”t, 3 
(23%) of 13 ptients treated with i”tIave”ws hepain had 
fibrinopepfide A kvck ~-10 “n&liter. 
No mnektion was fouwnd betwe” hbrinaprpcide A and 
bcdy weight except for P signifiaat direct relation between 
Sbrinopeptidc A cud body weight (I = 0.69, p = 0X09) in 
patienk treated tith subcutaacous heplrin 12 h after treat- 
“lent ““se‘ 
Figure 4 awnparcs chinges in the eol~entraticn of thrwn- 
bi”-antithmmbin 111 mmpkx in the tw patient groups. No 
@nitit diUerema were found bc:~mcn the tw groups. In 
the atnc”ce of hepark,, thrcmbin-a”tithrotdX” III mmplu 
inerewd s@iwtly at 2 h (from 8.3 2 2.3 to 13.7 + 
3.1 @ml, p = 0.01); in patienlg who received intravenau 
heparin, it decreased from 10.3 + 3.5 to 8.3 f 1.8 “&I (p = 
0.4) at the sane time point. 
Mode ot bqmrln admirdsimtion and rqwrfusiun. On rhc 
basis of characterization of the rate of incrwse I” the pknm.~ 
mncentntions of the CLMM3 isuform. 82% (23 of 2s) ot 
palienb achieved recanalizadon wilhin .? h from strqXo!iinw 
administration compared with Fd1 of pariunra ahcn the 
uileria of resolution of ST segment elwation were uacd. The 
Iwo criteria were discordwt in four patients (two classdicd as 
having reperfusion by MM3 but no inrprovemcnt in ST ceg- 
ment elevation. end IWO wirh resolution of ST segmenr &~a- 
tion but no accrler&on of MM3 washout). A significant 
tintion was found behveen the hvu noninvasive criteria 
(p = 0.04) for the diagnosis of comnery reperfusion. 
Table 2 shows the incident of coronary rcperfusion. as 
independently assessed b Ihc MM3 isoform and ST segment 
criteria, and infarct-related artery patency at late angiography 
in Ihe hw treament groups. No significant differences (p = 
0.6) were found belween pa&As treated wirh suhcslaneous 
versus intravenous hcparin. although a nonsignificant trend 
was found toward more rapid rcperfusion as characterized hy 
accelerated washout of MM3 at 1 h (p = 0.1) and greater 
Tbmmbin acrivity, intensity OF nnticoagtd&m and reper- 
Gun. Zguru 5 shows the concentrations of iibrinopeptide A 
in the liic patientswithout and the ?3p&x1saith rcpcrfusion 
;Q churxrerixd hy increases in rbe concentmtiuns of MM3 
W.15’; Jmin. At the end uf ~rrcptokhrase infusion, parients 
~bo did not achieve CK-MM isoform criteria for reperfusion 
had sigmtiomtly higher tibrinopeptide A lcvcls than cl;.’ “we 
with these criteria for repcrfusion (76.4 + 25.7 vs. 75.2 2 
5.2 nmol!liter. p = fl.O?). The same trend WI ubsewed in 
patknts with (n = 21) and without [n = 4) a >XlG decrease 
of ST segment elevation during continuous monitoring (re- 
spcctivcly. 27.9 ? 5.7 vs. h1.S 2 29.5 nmuliliter at 1 h, p = 
lJ.06). Also, patients with an occluded infarct-related artery by 
Iale euronary angiography had B strong trend toward higher 
fihrinopcptidc A levels at I h than did pzticnls with infarct- 
&ted artcry patency (4’1.9 i Id.6 ~5,. 23.4 2 5.0 nmol/liter, 
p = 0.06). No significant diikrenccs were found in thrombin- 
antithrombin III complex levels between patients with and 
without CK-MM isoform and ST segment criteria of repcrfu- 
&ion or patients with and without infarct-related artery patency. 
The degree of inhibition of thmmbin activity was found to 
be s:rkt!y dependent on the intensity of anticoagulation. Eight 
hours after streptokinase administration, patients with acti- 
vated partial th&hoplastin time proionged S2.0 times from 
baseline had significantly lower fibrinopeptide A levels thao 
did patients with lesser prolongation of activated partial 
rhromhoulastin time (5.8 + 1.4 vs. 32.8 f 10.1 nmollliter, o = 
0.02). F&hemmre, a signilirant correlation was found ‘he- 
tween fibrinopeptide A concentrations and the extent of 
prolongation of the activated partial thmmhoplastin time at 
24 h (p = 0.04). 
Discussion 
The main finding of the present study is that administration 
of tixed dose intravenous heoarin uartialk inhibits the eadv 
increase in thromhin activity &o&ted wiih infttsiott of sire{ 
tokinase. After initiation of Sxed dose subcutaneous heparin 
therapy. the xtent of lhrombht activity is similar to that after 
infusion of tixed dose intravenous hcparin despite a marked 
difference in the intensity of anticoagulation us judEed by 
activated partial thromboplastin time. However, holh heparin 
regimens me ineffective in suppressing thrombin activity, con- 
sidering the persistence of marked increases in tibtinopspdde 
A levels (i.e., >lO nmollliter) in -25% of patknls 81 48 h. 
Overall, these data suggest that trestmcnt with conjunctive 
fixed dose intravenous heparin inhibits thmmbin activity only 
modestly in vatients dven streotokinase and aspirin for acute 
myocar&al &farctioh These &dts are consistent with thee 
of the recently comoleted GUSTO trial of strestoklnaw. and 
rt-PA (22) in which mortality al 30 days was similar in patients 
receiving inttavenous or ~ubcutaneotts heparin in the strep 
tokinase amt. 
Ptwoagolaot activity during thmmboIysis ud i(a Inhlbl. 
tlon by hepria. The benefits of coronary thromhutysysb are 
limited by the lack of recanalization in -25% of patients and 
by the occurrence of rethrombosis in another 15% to 20% 
(2lJ3.24). Although mechanisms responsible for these phe- 
nomena have not yet been elucidated completely, there is 
evidence that increased thmmbin activity is a critical detcrtni- 
nsnt for both the failure of thromholysis and recurrent hrow 
basis (25-27). The results of several clinical studies are can- 
ristent with this hypothesis and indicate that both elaboration 
of thmmhin and thromhin activity increase in patients treated 
with librinolytic agents, particularly in those with unsum~sfttl 
clot lysis or reocclusion (l&15), or both. In keeping with these 
previous abservaiions, we observed a marked increase in both 
thromhin-antithrombin III complex and tibrinapeptide A lev- 
els at the end of streptakinase infusion in paticne not receiving 
intravenous heparin. Furthemtore, patients who did not meet 
criteria br tecanalilation at 1 h had significantly bigher 
tibrinopeptide A plasma concentrations than did patients with 
successful repafusion. 
In the present study, we assessed the effects on prumagu- 
lant activity of a SPW-IJ heparin bulus preceding streptoki- 
nave infusion. As previously observed (28). tibtinopeptide A 
levels still increased in patients treated with intraverous hep 
tin after thmmbolysi$ although this increase was significantly 
less than in the absence of heparin. Fixed dose intravenous 
he,:s:io therefore attenuated but did not completely prevent 
the increase in thrombin activity associated with streptokinax 
admbdstration. 
Mode oI hepario adminisbxdIon and thrumbin adIvIty. 
After the initiation of tixed duse sutataneous heparin ther- 
apy, thmmbin activity did not dilkr significantly between the 
hvo groups of patients, even though, in the patients treated 
with tixed dose intravenous heparin, median activated partial 
thromhoplastin time levels were, as expeaed, rignitkawly 
higher and well within the “thaapeutic” range in 70%. The 
quivalencc in inhibition of thrombin activity observed with 
both modes of hepatin administration is explained by the 
obwvation that lihrinopeptide Awes ittampletely suppressed 
in pw~tsgivcnfaed dose intravenoushcpmin. At 48 h -25% 
of patients had persistently elevated fibrinopeptidc A levels 
>I0 omokliter. This finding is in keeping with the results 
obtained by Mombelli et al. (29) in patients with acl:e 
myaardial iofarction not given lyiic therapy. III their patients, 
65% (i.e., 30 of 46) of sampks showed elevated fihrhtopeptide 
A concenlratiotts during the 1st 48 h of intravenous heparin 
treatment. Despite the sigoit?cattl relation between “adqua- 
cy” of antieangulation (activated partial lhromhoplatin time 
prolon@on ~2 times the baxelinc value) and tibrinopeptide 
A IN& also found in WI study, out results coi&mly 
indicate that faed dose intmveoous hepurin hw a variable sod 
often &optimal inhibitory efect on thmmbin activity and 
cInlmr&ion durioa xute mwcardial infarction treated with 
thromhoIytii a&s. l’hesz &dii$?s may lx due to the fact that 
clot-bound thrombin and factor Xa are ~&ally protected 
q&at hxparilhlntithrombin III inhibition (30-Z). 
Administration of tixed dose subcutaocous heparin initIuted 
4 h afterstreptokin~se therapy had a vwkhk and only modest 
c6ect on p&+@cm of th;-xtiwted partial thmmboplastitt 
lime. Four hours after the fint dose of sohcutanmus hewrio, 
scthrskd partial thromhoplwtitt lime was kss prolonged than 
nt the end of strcpto~asc inhtsiitt attd the pmbogation 
decreased progre&ely thereafter (the median value at 48 h 
wus 40 8) Only one Patient receiving suhcutancow hcparin 
had thempeutic levels of activated partial thmmtilaain time 
during th; study period; most paiients had a&ted partial 
thmtnhodastin time omlottwd X.5 but <2.0 times the base- 
line val& These fin&s &tintt the results of Kmon et al. 
(a), who studied, on day 4 after thrombolytic therapy, eight 
patients with suspected or definite ucute myawdial infarction 
who pxtkipatcd in the Third International Study of Iofarct 
Suwivul (ISIS-3). Whether these minor prolongations of the 
activated partial thmmhoplastin time c&rib& to the pro- 
me&e decrease in librinoowtide A levels observed over 48 h 
-&mot b: axettaincd by th> &en1 data, given the absence of 
B contml group to determine w!!ether thmmbin activity de- 
creases even in the absence uf lteparin. 
IZects dhepaiin uo ~prfuslott. Conjunctive intravenous 
heparin trearment was repwed by Melandri et al. (33) to 
accelerate reps&ion in patients given streptokina%. In our 
study the wcorr~nce of reperfusion wils assessed by two 
independent nonimasive cntena: the rate of mcrease of CK- 
MM3 isoform and continuous ST segnent monitoring. Ai- 
though our study did not have sufficient statistical powr t(> 
draw negative conclusions, both techniqurr faded to reveal 
significant diifcrences in r-&r: and timing of repcrfosion be- 
tween patients with or wi!hout pretreatment wlrh iwavenow 
hepar& This iinding is in keeping with the recently pub;lshrd 
GUSTO sneioemohic substudv (.%I1 in whxh no diffennccs in 
9C-min ang&gnphic patency &‘detected in patients given 
streptokinasc with or without prefwatmcnt with infwcnour 
heparin. Heparin has also been shown to hare httlr mflucnce 
on the resprnre to thrombolytic therapy in rx~rimcnt4 
models even when administered au doxs that rcxdt I” d 
marked anticoagulant effect in viva (2735). Because the role of 
platelets during thromhoiysis appears vev important (Xh). 
particularly in enhancing the response to strcptohnarc (23). 
the more aggressive us of aspirin in our study with respect to 
the study of Mekmdri et al. (33) mily in part eapizain the 
differences between the tw studies. In our study .uspiris was 
given before the initiation of iytic trwtment rather than at the 
end of ‘eparin infusion (i.e., 4 to 5 cidys after thrombolysis). 
Study limitations_ An important limitation of our study i\ 
that we used a iixed dose heparin infusion (ISNil U/h) rathc! 
than adjosting the dew on the basis of ariveted partial 
thwmbopiastin time. Our appmach could have iimacd the 
degree to which thrombin activity was suQQr~Wd. 111 iidditton. 
reperfusion was sassed by noninvasive methods rnthur than 
hy acute angiography. However, the methods (i.e.. enzyme 
determinations and continuous ECG monituring) &we co~~coc- 
dam results in our study group and, used independently. have 
heen extensively validated against angiognphy in large scale 
trisis (3738). 
Ccmclusioas. The results of our study indicate that the 
degree of inhibition of thmmbin activity achieved by tied dose 
intmvenaus hepmin compared with that achieved with subcu- 
taneous hcparin in patients given streptakinase and aspirin for 
acute myocardiai infarction is similar but incomplete. Ai- 
though thrombin activity increases during administration of 
streptokinasc, pretreating pa:ients with an intrwenous hepnrin 
bolos confers no sdvantage in terms of the overall rate of 
rcperfusion rate. Our findings provide B biochemical explana- 
tion for the failure of conjuntiivc intravenous heparin to 
improve survival in the GUSTO trial. Qversll, our results 
suggest that heparin may be an inadequate inhibitor of throm- 
bin during thromboiysis with streptokinasc. Perhaps newer. 
more potent and more specific antithrombin agents will im- 
prove the extent of thrombin inhibition and therefore the 
outcome of tbmmboiytic therapy with streptokinase. 
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